[1]

Senthil S, Dada T, Das T, Kaushik S, Puthuran GV, et al. 2021. Neovascular glaucoma - A review. Indian Journal of Ophthalmology 69(3):525−34

doi: 10.4103/ijo.IJO_1591_20
[2]

Shazly TA, Latina MA. 2009. Neovascular glaucoma: etiology, diagnosis and prognosis. Seminars in Ophthalmology 24(2):113−121

doi: 10.1080/08820530902800801
[3]

Dastiridou AI, Katsanos A, Denis P, Francis BA, Mikropoulos DG, et al. 2018. Cyclodestructive procedures in glaucoma: a review of current and emerging options. Advances in Therapy 35(12):2103−2127

doi: 10.1007/s12325-018-0837-3
[4]

Mastropasqua R, Fasanella V, Mastropasqua A, Ciancaglini M, Agnifili L. 2017. High-intensity focused ultrasound circular cyclocoagulation in glaucoma: a step forward for cyclodestruction? Journal of Ophthalmology 2017:7136275

doi: 10.1155/2017/7136275
[5]

Wang R, Ding W, Jiang L, Fan F, Li N, et al. 2023. A comparative study of ultrasound cycloplasty and endoscopic cyclophotocoagulation in the treatment of secondary glaucoma. Scientific Reports 13(1):23073

doi: 10.1038/s41598-023-50157-6
[6]

Charrel T, Aptel F, Birer A, Chavrier F, Romano F, et al. 2011. Development of a miniaturized HIFU device for glaucoma treatment with conformal coagulation of the ciliary bodies. Ultrasound in Medicine and Biology 37(5):742−754

doi: 10.1016/j.ultrasmedbio.2011.01.017
[7]

Giannaccare G, Sebastiani S, Campos EC. 2018. Ultrasound cyclo plasty in eyes with glaucoma. Journal of Visualized Experiments 131:e56192

doi: 10.3791/56192
[8]

Aptel F, Charrel T, Palazzi X, Chapelon JY, Denis P, et al. 2010. Histologic effects of a new device for high-intensity focused ultrasound cyclocoagulation. Investigative Ophthalmology & Visual Science 51(10):5092−5098

doi: 10.1167/iovs.09-5135
[9]

Zhou L, Hu D, Lan J, Liu Y, Lv M, et al. 2022. Efficacy and safety of single Ultrasound Cyclo-Plasty to treat refractory glaucoma: results at 1 year. European Journal of Ophthalmology 32(1):268−274

doi: 10.1177/1120672120973605
[10]

Gerçeker Demircan S, Şanal Doğan A. 2025. Neovascular glaucoma: comprehensive evaluation of etiology, treatment modalities, and visual prognosis. BMC Ophthalmology 25:540

doi: 10.1186/s12886-025-04389-x
[11]

Yun JS, Santina A, Tseng VL. 2025. Medical and surgical management of neovascular glaucoma. Current Opinion in Ophthalmology 36(5):434−441

doi: 10.1097/ICU.0000000000001151
[12]

Noma H, Yasuda K, Shimura M. 2020. Cytokines and pathogenesis of central retinal vein occlusion. Journal of Clinical Medicine 9(11):3457

doi: 10.3390/jcm9113457
[13]

Gupta D, Chen PP. 2016. Glaucoma. American Family Physician 93(8):668−674
[14]

Al Sarireh F, Alrawashdeh HM, Al Zubi K, Al Salem K. 2021. Role of bevacizumab intraocular injection in the management of neovascular glaucoma. nternational Journal of Ophthalmology 14(6):855−859

doi: 10.18240/ijo.2021.06.10
[15]

Valtot F, Kopel J, Haut J. 1989. Treatment of glaucoma with high intensity focused ultrasound. International Ophthalmology 13(1−2):167−170

doi: 10.1007/BF02028659
[16]

Almobarak FA, Alrubean A, Alsarhani W, Aljenaidel A, Osman EA. 2022. Outcomes and predictors of failure of ultrasound cyclo plasty for primary open-angle glaucoma. Journal of Clinical Medicine 11(22):6770

doi: 10.3390/jcm11226770
[17]

Giannaccare G, Vagge A, Sebastiani S, Urbini LE, Corazza P, et al. 2019. Ultrasound cyclo-plasty in patients with glaucoma: 1-year results from a multicentre prospective study. Ophthalmic Res 61(3):137−142

doi: 10.1159/000487953
[18]

Giannaccare G, Pellegrini M, Bernabei F, Urbini L, Bergamini F, et al. 2021. A 2-year prospective multicenter study of ultrasound cyclo plasty for glaucoma. Scientific Reports 11:12647

doi: 10.1038/s41598-021-92233-9
[19]

Almobarak FA, Alrubean A, Alsarhani WK, Aljenaidel A, Osman EA. 2022. Ultrasound cyclo plasty in glaucoma: 2-year outcomes. Journal of Glaucoma 31(10):834−838

doi: 10.1097/IJG.0000000000002078
[20]

Fan FF, Ge X, Liu DD, Xu TY, Wang RX, et al. 2023. Comparison of the efficacy and safety of ultrasonic cycloplasty vs valve implantation and anti-VEGF for the treatment of fundus disease-related neovascular glaucoma. International Journal of Ophthalmology 16(6):897−903

doi: 10.18240/ijo.2023.06.10
[21]

Sun H, Zou W, Zhang Z, Huang D, Zhao J, et al. 2022. Vitreous inflammatory cytokines and chemokines, not altered after preoperative adjunctive conbercept injection, but associated with early postoperative macular edema in patients with proliferative diabetic retinopathy. Frontiers in Physiology 13:846003

doi: 10.3389/fphys.2022.846003
[22]

Cheng JW, Cheng SW, Wei RL, Lu GC. 2016. Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery. The Cochrane Database of Systematic Reviews 2016(1):CD009782

doi: 10.1002/14651858.cd009782
[23]

He CZ, Lu SJ, Zeng ZJ, Liu JQ, Qiu Q, et al. 2024. The efficacy and safety of anti-vascular endothelial growth factor combined with Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a systematic review and meta-analysis. Frontiers in Medicine 11:1405261

doi: 10.3389/fmed.2024.1405261
[24]

Kooner KS, Choo DM, Mekala P. 2024. Meeting Challenges in the Diagnosis and Treatment of Glaucoma. Bioengineering 12(1):6

doi: 10.3390/bioengineering12010006
[25]

Ryoo NK, Lee EJ, Kim TW. 2013. Regression of iris neovascularization after subconjunctival injection of bevacizumab. Korean Journal of Ophthalmology 27(4):299−303

doi: 10.3341/kjo.2013.27.4.299
[26]

Bolek B, Wylęgała A, Wylęgała E. 2023. Ultrasound ciliary plasty in glaucoma treatment: a long-term follow-up study. Acta Ophthalmologica 101(3):293−300

doi: 10.1111/aos.15290